These include entinostat/MS-275 and NKL54, which favor class I enzymes other than HDAC8, and chidamide/CS055, which has been approved by the China Food and Drug Administration for peripheral T-cell lymphoma and advanced breast cancer[189]. The gene discussed is HDAC8; the disease is peripheral T-cell lymphoma, not otherwise specified.